Spero Therapeutics Q1 net loss $12.7M; SPR720 Phase 2a data expected 2H 2024

Spero Therapeutics, Inc.

2024-Q1 EPS reported -$0.24 revenue$9,267,000

Net loss $12.7M ($0.24/share) vs $13.3M ($0.25/share) in Q1 2023; revenue $9.3M up from $2.1M.
Cash $82.3M at March 31, 2024, increased from $76.3M after receiving $23.8M milestone from GSK for tebipenem HBr.
SPR720 Phase 2a top-line data for NTM-PD expected 2H 2024; tebipenem HBr Phase 3 PIVOT-PO enrollment ongoing, completion 2H 2025.
SPR206 received FDA Fast Track designation for HABP/VABP due to CRABc and CRPA; Phase 2 contingent on non-dilutive funding.
Reaffirmed cash runway into late 2025 based on current operating plans.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Spero Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $9.3 million, net income net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted, EPS ($0.24) per share.

Period: the first quarter ended March 31, 2024
Revenue: $9.3 million
Net income: net loss of $12.7 million, or ($0.24) per share of common stock, basic and diluted
EPS: ($0.24) per share
Result: reported results

Exact text from the filing

net loss of $13.3 million, or ($0.25) per share of common stock, basic and diluted, for the first quarter ended March 31, 2023. • Total revenue for the first quarter of 2024 was $9.3 million, compared with total revenue of $2.1 million for the first quarter of 2023. The revenue increase for the first quarter of 2024 was primarily due to an increase in collaboration

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Spero Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-139364

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.